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Purpose: The purpose of this study was to determine the safety and durability of traditional surgical treatment for
asymptomatic infrarenal abdominal aortic aneurysms (AAAs) in a large series of patients who underwent open operations
during the decade preceding the commercial availability of stent graft devices for endovascular AAA repair.
Methods: From 1989 to 1998, 1135 consecutive patients (985 men [87%], 150 women; mean age, 70  7 years)
underwent elective graft replacement of infrarenal AAA. Computerized perioperative data have been supplemented with
a retrospective review of hospital charts/outpatient records and a telephone canvass to calculate survival rates and the
incidence rate of subsequent graft-related complications. Seventy-four patients (6.5%) were lost during a median
follow-up period of 57 months for the entire series.
Results: The 30-day mortality rate was 1.2%. The hospital course was completely uneventful for 939 patients (83%), and
the median length of stay for all patients was 8 days. A total of 196 patients had single (n  150; 13%) or multiple (n 
46; 4%) postoperative complications, which were more likely to occur in men (odds ratio [OR], 2.3; 95% confidence
interval [CI], 1.1 to 5.2) and in patients with a history of congestive heart failure (OR, 3.7; 95% CI, 1.7 to 7.8), chronic
pulmonary disease (OR, 1.9; 95% CI, 1.2 to 2.9), or renal insufficiency (OR, 2.5; 95% CI, 1.3 to 4.7). Kaplan-Meier
method survival rate estimates were 75% at 5 years and 49% at 10 years. As was the case with early complications, the
long-term mortality rate primarily was influenced by age of more than 75 years (risk ratio [RR], 2.2; 95% CI, 1.7 to 2.8)
or previous history of congestive heart failure (RR, 2.1; 95% CI, 1.3 to 3.4), chronic pulmonary disease (RR, 1.5; 95% CI,
1.2 to 2.0), or renal insufficiency (RR, 3.2; 95% CI, 2.2 to 4.6). Of the 1047 patients who survived their operations and
remained available for follow-up study, only four (0.4%) have had late complications that were related to their aortic
replacement grafts.
Conclusion: These results reconfirm the exemplary success of open infrarenal AAA repair. The future of endovascular AAA
repair is exceedingly bright, but until the long-term outcome of the current generation of stent grafts is adequately
documented, their use should be justified by the presence of serious surgical risk factors. (J Vasc Surg 2002;35:1145-54.)
Half a century has passed since DuBost, Allary, and
Oeconomos1 described the first successful replacement of
an infrarenal abdominal aortic aneurysm (AAA) with a
homograft. Since that time, progress in the surgical treat-
ment of AAAs has been marked by remarkable advances in
graft materials, operative techniques, and anesthesia man-
agement. Classic references, such as those by Szilagyi et al2
and Crawford et al,3 defined the appropriateness and the
declining mortality rate of elective AAA repair, and recent
data have again confirmed that spontaneous rupture is
associated with such a low chance for survival that preemp-
tive intervention is justified for AAAs of appropriate size
even in the presence of medical comorbidities.4,5 In this
regard, studies by Cronenwett et al6,7 have suggested that
hypertension and chronic obstructive pulmonary disease
(COPD), rather than representing surgical contraindica-
tions, actually encourage further aneurysm enlargement
and eventual rupture.
The latest contribution to the treatment of AAAs—
endoluminal stent grafting—was introduced in 1991 by
Parodi, Palmaz, and Barone,8 originally as an alternative to
open repair in high-risk surgical candidates. During the
decade since this landmark report was published, a growing
array of proprietary stent graft devices has been used exten-
sively in Europe and has been tested in the setting of clinical
trials in the United States. Two of these (Guidant Ancure,
Menlo Park, Calif; and Medtronics AneuRx, Minneapolis,
Minn) have been given market approval in the United
States by the Food and Drug Administration. Endovascular
aneurysm repair currently is the topic of so many profes-
sional articles and symposia that vascular surgeons who do
not yet perform stent grafting may have begun to wonder
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whether their traditional open approach already has be-
come obsolete. Endovascular repair also has received wide
attention in the lay press and on the Internet, and many
patients who do not have any serious surgical risk factors
seem to have the impression that stent grafting has now
become the procedure of choice for all AAAs.
Should endovascular AAA repair be offered routinely to
patients at average or good risk? Until the late outcome of
stent graft devices is better known, the answer to this
question will depend in large measure on the relative risk
and durability of open procedures. To document contem-
porary results at our own center, we have reviewed our
experience with conventional AAA repair during the de-
cade from 1989 to 1998.
MATERIAL AND METHODS
During this study period, a total of 1293 consecutive
patients underwent isolated open repair of AAAs that were
located below the level of the renal arteries and were not
associated with simultaneous renal, mesenteric, or femoro-
popliteal revascularization. Urgent procedures were neces-
sary for 158 of these patients because of symptomatic intact
(n  74) or ruptured (n  84) aneurysms. The remaining
1135 patients underwent elective operations for aneurysms
measuring 5 cm or more in diameter and comprise our
study group. Perioperative information was retrieved from
their hospital charts, 39 (3.4%) of which no longer were
available because they had been destroyed or misplaced
during warehousing after 5 years of patient inactivity at our
center. However, all postoperative deaths or complications
and the essential elements of the preoperative history, the
clinical cardiopulmonary status, and baseline renal function
were prospectively recorded in our departmental computer
registry. The only data that are missing for these 39 patients
are whether they underwent functional myocardial imaging
or cardiac catheterization or both before surgery.
Our practice customarily is to see patients with uncom-
plicated conditions at 1 year and then every 3 to 5 years
with a contrast-enhanced computed tomographic (CT)
scan of the descending thoracic aorta and the visceral aortic
segment to rule out the possibility of new proximal aneu-
rysms. Complete follow-up information was collected on
the basis of a review of the outpatient records and a year-
long telephone canvass of patients, their surviving family
members, or their referring physicians. Seventy-four patients
(6.5%) were lost during a median follow-up interval of 57
months (mean, 58.9 34.9 months) for the entire series.
Patient characteristics. As indicated in Table I, this
series includes 985 men (87%) and 150 women (13%) with
age ranging from 44 to 94 years (mean, 70.5  7.2 years;
median, 70 years). The mean diameter of AAA was 5.7 
1.1 cm with ultrasonography and 6.0  1.3 cm with CT
scanning. Eight hundred and seventeen patients (74%) had
hypertensive conditions (blood pressure, 180/90 mm Hg)
or needed antihypertensive medications, and only 79
(7.0%) had diabetes. Coronary artery disease (CAD) was
suspected clinically in 735 patients (65%) because of either
a convincing history of previous angina pectoris or myocar-
dial infarction (MI) or the presence of a Q-wave or ischemic
ST-T wave changes on a standard 12-lead electrocardio-
gram. Thirty-eight patients (3.3%) had a history of conges-
tive heart failure (CHF). Clinical evidence of COPD was
present in 275 patients (24%) but was investigated with
functional testing only when it obviously was disabling.
The preoperative serum creatinine level was 2 mg/dL or
more in 57 patients (5.0%), and another nine patients
(0.8%) needed maintenance hemodialysis.
Preoperative cardiac assessment. We have believed
for many years that optimization of the preoperative cardiac
status contributes substantially to the safety of elective
vascular surgery.9-12 Accordingly, we routinely perform
some type of objective cardiac screening before elective
AAA repair unless a specific reason exists not to do so, such
as previous satisfactory testing within the previous year, a
relatively recent history of successful coronary artery bypass
grafting (CABG) or percutaneous transluminal coronary
angioplasty (PTCA), or the presence of documented CAD
for which no corrective intervention is feasible. The cardiac
data that are presented in Table II were obtained within 6
months before the index AAA procedure, an interval that
captures all routine preoperative studies but also includes
patients who may have first been discovered to have AAAs at
the time they were referred to our center because of CAD.
Dipyridamole-thallium scanning or dobutamine-stress
echocardiography was obtained in 636 of the 1135 patients
(56%). Sixteen patients underwent both of these studies to
Table I. Patient characteristics
n %
Patients 1135 100
Men 985 87
Women 150 13
Age (years)
Range 44-94
Mean 70.5  7.2
Median 70
Mean aneurysm diameter (cm)
Ultrasonography (n  689) 5.7  1.1
CT (n  828) 6.0  1.3
Hypertension 817 74
Diabetes 79 7
Insulin-dependent 15 1
Clinical cardiac risk factors
None 362 32
CAD 735 65
CHF 38 3
Clinical pulmonary risk factors
None 860 76
COPD 275 24
Renal risk factors
Creatinine  2 mg/dL 1069 94
Creatinine 2-3 mg/dL 45 4
Creatinine  3 mg/dL 12 1
Prior dialysis 9 1
Replacement graft configuration
Straight 337 30
Aortobiiliac 736 65
Aortobifemoral 40 3
Aortoiliac/femoral 22 2
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clarify their findings, and 23 other patients underwent only
a stress electrocardiogram. Active myocardial ischemia was
identified in 104 of the 636 patients (16%) who had func-
tional imaging studies. Coronary angiography was per-
formed in 529 patients (47%), revealing severe but correct-
able CAD that appeared to place viable myocardium at risk
in 154 (29%).9 Only 121 of the 1135 patients (11%) were
not known to have had either functional myocardial imag-
ing or coronary angiography. A total of 174 patients (15%)
underwent CABG (n 119; 10%) or PTCA (n 55; 4.8%)
during the 6 months preceding their AAA operations,
including 153 of the 154 patients who had severe correct-
able CAD. (The other 20 patients had miscellaneous indi-
cations for coronary intervention. Nine of them underwent
PTCA [n  8] or CABG [n  1] for advanced but
compensated CAD, including three who had active myo-
cardial ischemia on functional imaging. The results of cor-
onary angiography were unknown for six patients who
underwent incidental PTCA [n  3] or CABG [n  3]
elsewhere, and CABG was performed for two patients in
conjunction with replacement of either the aortic valve or
the ascending thoracic aorta. The remaining three charts
were unavailable for review.) One hundred and eighteen of
these 174 procedures (68%) were done as a direct result of
the preoperative cardiac evaluation, and 56 patients had
incidental AAAs that were repaired during staged proce-
dures after primary coronary intervention. Another 332
patients (29%) had a remote history of unrelated CABG or
PTCA or both.
Surgical considerations. All AAA procedures were
performed with general endotracheal anesthesia, usually
together with epidural analgesia for postoperative pain
management. Although a midline transperitoneal incision
was used preferentially, an extraperitoneal approach
through the left flank was used whenever it seemed to be
more appropriate because of truncal obesity, serious
COPD, or the possibility that suprarenal cross clamping
might be necessary for construction of a juxtarenal aortic
graft. (Our database does not contain specific information
regarding the choice of incisions.) Collagen-impregnated
polyester fiber (Dacron) replacement grafts were implanted
in 1127 patients, and the remaining eight patients received
polytetrafluoroethylene grafts. Straight grafts were feasible
in 337 patients (30%), but aortobiiliac (n  736), aortob-
ifemoral (n  40), or aortoiliac/femoral (n  22) bifurca-
tion grafts were used in most cases (70%; Table I).
Statistical analysis. Baseline preoperative data in-
cluded gender, age, and conventional risk factors (Table I),
the information obtained with noninvasive cardiac testing
or coronary angiography (Table II), and a number of
miscellaneous considerations, such as the year of operation,
whether the AAA procedure represented a reoperation, and
the configuration of the aortic replacement graft. These
features were investigated for their possible relationship to
postoperative outcomes, including 30-day mortality, long-
term survival, and a total of 30 potential perioperative
complications that are designated on our departmental
registry form. These complications were subclassified in the
following principal categories: cardiac, pulmonary, renal,
gastrointestinal, stroke, reconstruction-related (eg, bleed-
ing, thrombosis, infection), wound-related (eg, hematoma,
infection, dehiscence), and miscellaneous (eg, amputation,
deep vein thrombosis, sepsis).
Perioperative complication rates were assessed primar-
ily with logistic regression analysis. Kaplan-Meier method
estimates of survival rate distribution were generated for
overall survival rate and for survival rate by age, cardiac risk,
prior CHF, COPD, renal function, and all other baseline
factors. The relationships between these factors and survival
rate were assessed with log-rank testing. Risk factors that
were found to be significant were considered for multivari-
able analysis with the Cox proportional hazards model.
Risk ratios and their 95% confidence intervals (CIs) indicate
the risk at any point in time for the index group in compar-
ison with the reference set. A significance level of .05 was
used for each hypothesis. All analyses were performed with
SAS statistical software (Cary, NC).
RESULTS
Postoperative complications. Fourteen deaths oc-
curred within the first 30 postoperative days, for an opera-
tive mortality rate of 1.2%. Three of these deaths were
cardiac-related (Table III). Three other deaths were related
to pulmonary complications, four to multisystem organ
failure, and the remaining four to miscellaneous causes.
Nine hundred and thirty-nine patients (83%) had no
complications of any kind, and the median hospital length
of stay was 8 days (quartiles: 7 days, 11 days) for the entire
series. The median postoperative length of stay declined
from 10 days in 1989 to 8 days in 1998 (P .001), and the
median length of the entire hospitalization (including pre-
operative days) declined from 13 days in 1989 to 8 days in
Table II. Preoperative cardiac status
n %
Functional myocardial imaging* 636 56
Normal 374 59
Fixed scar 127 20
Active ischemia 104 16
Inconclusive† 31 5
Coronary angiography 529 47
Normal 15 3
Mild to moderate CAD 117 22
Advanced but compensated CAD 239 45
Severe correctable CAD 154 29
Severe uncorrectable CAD 4 1
Previous coronary bypass surgery 395 35
Remote (6 months) 276 70
Recent incidental 52 13
Planned preliminary 67 17
Previous transluminal coronary angioplasty 111 10
Remote (6 months) 56 50
Recent incidental 4 4
Planned preliminary 51 46
*Dipyridamole-thallium scintigraphy (n 376) or dobutamine-stress echo-
cardiography (n  276).
†Failed to attain at least 85% of predicted maximal heart rate during stress
testing.
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 6 Hertzer et al 1147
1998 (P  .001). Single complications occurred in 150
patients (13%), and 46 patients (4.1%) had multiple com-
plications (Table III). Cardiac complications were most
common (5.2%), but most of these (38/59) were confined
to arrhythmias that responded to medical management. At
least one set of postoperative cardiac isoenzymes was rou-
tinely obtained in most patients, and 16 perioperative MIs
(1.4%) were documented. Postoperative pulmonary events
occurred in 4.1% of patients, wound complications in 3.3%,
and renal insufficiency (defined as an increase in the serum
creatinine level of 1 mg/dL or more in comparison with the
preoperative value) in 1.7%. Only six patients (0.5%) who
were not undergoing preoperative dialysis needed new
dialysis after surgery, however, and the incidence rate of
most other serious complications was similarly low. Forty-
five early reoperations were necessary in 28 patients (2.5%),
the most frequent indication being a fascial wound dehis-
cence (n  15; 1.3%).
Significant results of the multivariable analysis of 30-
day complications are presented in Table IV. The overall
complication rate was higher in men and in patients who
had a previous history of CHF, COPD, renal insufficiency,
or dialysis. Advancing age contributed to the incidence of
cardiac complications. Otherwise, the incidence of organ-
specific (ie, cardiac, pulmonary, or renal) complications was
predictably related to preoperative risk factors, such as
CHF, remote CABG, COPD, and severe renal dysfunction.
Late survival. In addition to the 14 postoperative
deaths, another 300 of the 1185 patients (25%) eventually
died at a mean follow-up interval of 44.4  31.6 months
(median, 38 months). The principal causes of these 314
deaths were cardiac in 23% (MI, 12%; CHF, 6%; arrhyth-
mias, 5%), cancer in 20%, pulmonary in 5%, renal in 4%, and
stroke in 3%. Miscellaneous events were responsible for 4%
of all deaths, but the cause of death was unavailable for 130
patients (41%). Kaplan-Meier method estimates of long-
term survival rates for the entire series of patients are 94%
(95% CI, 93% to 95%) at 1 year, 75% (95% CI, 72% to 78%)
at 5 years, and 49% (95% CI, 43% to 54%) at 10 years (Fig
1, A). Late survival rate has been significantly influenced by
age (Fig 1, B; P  .001), by a clinical history of CAD (Fig
2, A; P .028), and especially by a history of previous CHF
(Fig 2, B; P  .001). Survival rates also have been less
favorable in patients who had preoperative COPD (Fig 3,
A; P  .001) or renal risk factors (Fig 3, B; P  .001),
defined as an elevated serum creatinine level (2 mg/dL)
or chronic renal failure that already necessitated dialysis.
Additional Kaplan-Meier method survival rate esti-
mates are summarized in Table V. The difference between
the 10-year survival rates for men and women did not attain
statistical significance (P  .072). For reasons that are not
clear, significant differences in late survival rate appear to be
associated with the configuration of the aortic replacement
graft (P  .03) and with whether patients sustained post-
operative wound complications (P .019). Overall survival
rate trends among subsets of patients who underwent pre-
operative functional myocardial imaging (P  .015) or
coronary angiography (P  .29) are difficult to interpret
because all but one of the 154 patients who were found to
have severe correctable CAD underwent CABG or PTCA
within the 6 months preceding their aneurysm procedures.
Thirty of the 104 patients (29%) who had active myocardial
ischemia on functional imaging received some form of
coronary revascularization, a feature that may have contrib-
uted to their good long-term survival rate. The survival
rates for 121 patients who were not known to have had
Table III. 30-day mortality and complication rates
n %
Deaths
Cardiac 3 0.3
Pulmonary 3 0.3
Multisystem organ failure 4 0.3
Other causes 4 0.3
Any complication
None 939 83
Single 150 13
Multiple 46 4
Cardiac complications
Arrhythmia 38 3
MI 16 1
CHF 10 1
Pulmonary complications
Pneumonia 35 3
Adult respiratory distress syndrome 13 1
Pulmonary embolism 2 0.2
Renal complications
Nonoliguric 11 1
Oliguric 8 0.7
(New dialysis) (6) (0.5)
Miscellaneous complications
Wound 38 3
Intestinal obstruction 14 1
Intestinal ischemia 11 1
Sepsis 8 0.7
Retroperitoneal bleeding 5 0.4
Stroke 4 0.4
Lower extremity DVT 4 0.4
Amputation 1 0.1
DVT, Deep vein thrombosis.
Table IV. Multivariable analysis of 30-day complications
Significant risk factors
Odds
ratio 95% CI P value
All complications
Men 2.3 1.1, 5.2 .035
Prior CHF 3.7 1.7, 7.8 .001
COPD 1.9 1.2, 2.9 .004
Creatinine  2 mg/dL or prior
dialysis
2.5 1.3, 4.7 .006
Cardiac complications
Decile age increments 1.5 1.0, 2.2 .035
Prior CHF 4.8 2.0, 11 .001
Remote coronary bypass surgery 2.0 1.1, 3.6 .015
Pulmonary complications
COPD 2.6 1.4, 4.8 .002
Renal complications
Creatinine  2 mg/dL or
prior dialysis
6.2 2.2, 17 .001
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either functional imaging or coronary angiography were
90% at 1 year, 74% at 5 years, and 32% at 10 years.
Significant results of the multivariable analysis of all
deaths are presented in Table VI. In addition to graft
configuration, the same factors that are shown with the data
in Table IV to be associated with higher postoperative
complication rates—advanced age and previous CHF,
COPD, or renal insufficiency—also have been the principal
predictors of late death in this series.
Late graft complications. With the exclusion of the
14 patients who died after surgery and the 74 patients who
eventually were lost to follow-up study, 1047 of the 1135
patients in this series were eligible for consideration regard-
ing late complications of their aortic replacement grafts. On
the basis of a review of current outpatient records and a
year-long telephone canvass to obtain information for pa-
tients who had not recently undergone reexamination at
our center, we were able to identify only four late graft
complications (0.4%). These complications included two
graft infections, one graft limb occlusion, and one femoral
pseudoaneurysm in a patient for whom an aortobifemoral
graft had been constructed during AAA repair. With the
concession that we do not conduct routine surveillance of
infrarenal aortic grafts with ultrasonography or any other
imaging technique, we are not aware that any of these 1047
patients has necessitated a reoperation for a proximal aortic
pseudoaneurysm.
DISCUSSION
Endovascular repair represents a dramatic technical ad-
vance in the management of infrarenal AAAs and already
provides a relatively safe alternative to traditional open
operations in truly high-risk surgical candidates. Cuypers et
al13 recently concluded, for example, that endovascular
Fig 1. Kaplan-Meier method 10-year survival rate estimates for (A) all patients and (B) age quartiles.
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repair may have a lower risk for perioperative myocardial
ischemia because of significant intraoperative differences in
the cardiac index and the left ventricular stroke work index
compared with open procedures. On the basis of their
phase II clinical trials, both of the stent graft devices that
have received Food and Drug Administration market ap-
proval in the United States can be deployed successfully in
most patients with suitable aortic anatomy (Guidant An-
cure, 94%; Medtronics AneuRx, 98%) and are associated
with a low periprocedural mortality rate of approximately
2%.14,15 Nevertheless, the durability of aortic stent grafts
has not yet been determined, particularly with respect to
the long-term implications of intrasac endoleaks caused by
insecure attachment sites (type I), retrograde flow in
branch vessels (type II), or midgraft defects (type III).
Centers that participated in the phase II AneuRx trial
reported early endoleaks in 38% of patients, and although
only about a third of these persisted for longer than 1
month on follow-up imaging, new endoleaks eventually
occurred in another 9% of patients and secondary proce-
dures to correct endoleaks (4%) or graft limb occlusions
(2%) ultimately were necessary in a total of 6% of patients.15
According to Zarins et al,16,17 the presence of an endoleak
has not influenced the cumulative 1-year survival rate (96%)
or the 2-year aneurysm rupture rate (3%) in the phase II
AneuRx trial. In Europe, however, both type I and type III
endoleaks have significantly contributed to the cumulative
rupture rate of 1% per year for AAAs treated with several
proprietary stent grafts in the EUROSTAR registry.18
The primary outcome success rate, defined as freedom
from death, aneurysm rupture, conversion to open repair,
or secondary procedures for endoleak or graft occlusion,
Fig 2. Kaplan-Meier method 10-year survival rate estimates on basis of (A) any cardiac risk factor and (B) previous CHF.
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was 88% at a follow-up interval of 18 months for 398
patients in the phase II AneuRx trial.16 The 30-day techni-
cal success rate was only 72% for the first 1554 patients in the
EUROSTAR database, but this term was stringently de-
fined in the sense that it included deployment failure and all
endoleaks in addition to death, aneurysm rupture, and
secondary transabdominal intervention.19 The EURO-
STAR collaborators subsequently reported an annual open
conversion rate of 2.1% during the initial 4 years of fol-
low-up study in a larger cohort of 2464 patients, with an
operative mortality rate of 24% for these 41 procedures.18
None of these studies can anticipate whether such factors as
proximal aortic dilation or material fatigue will cause addi-
tional stent graft complications in the future, but this
uncertainty is another feature that calls into question
whether endovascular AAA repair should presently be con-
sidered for patients who have no particular contraindica-
tions to a standard surgical approach. Precedence exists in
surgical technology for concerns of this kind. Prosthetic
cardiac valves, for example, have undergone many refine-
ments in a continuing attempt to reduce their late compli-
cation rate. Perhaps the most important difference in any
simile between these devices and aortic stent grafts is the
fact that there was no therapeutic alternative for the re-
placement of diseased valves at the time that the original
caged-ball prosthesis was introduced, whereas a safe, de-
pendable operation already is available for infrarenal AAAs,
especially in patients at average or good risk.
How safe is open AAA repair specifically in these two
groups of patients? There is no easy answer because nearly
the entire literature on the topic of asymptomatic AAAs,
including our report, is on the basis of nonuniform patient
Fig 3. Kaplan-Meier method 10-year survival rate estimates on basis of (A) COPD and (B) any renal risk factor.
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populations having a wide variety of surgical risks. Repre-
sentative data for elective procedures are summarized in
Table VII. Collective reviews have cited several series from
referral centers in which the operative mortality rate (2%) is
comparable with our own (1.2%),20-22 and the mortality
rate in multicentered cooperative studies generally has been
about 5%.23-25 Statewide audits have documented early
mortality rates exceeding 7% for nonruptured AAAs but
also have repeatedly shown that these rates are inversely
related to the hospital volume and the experience of indi-
vidual surgeons with aortic surgery.26-28 The Dartmouth
Atlas of Vascular Health Care has confirmed that this
relationship between case volume and early outcome exists
nationwide in the Medicare population, irrespective of the
specialty designation of the surgeons performing the oper-
ations.32 Recent investigations with the National Hospital
Discharge Survey have the advantage of an extraordinarily
large database but necessitate considerable editing even to
discriminate between suprarenal and infrarenal aortic aneu-
rysms.29-32 Possibly because of differences in the way in
which data were retrieved from the National Hospital Dis-
charge Survey, these investigations have estimated that the
overall mortality rate for AAA repair in the United States
ranges as much as from 4% to 8%. Comparison of any of
these figures with the postoperative mortality rate for en-
dovascular AAA repair at vetted trial centers could be
misleading because, in addition to potential variability in
patient mix, the mortality rate of endovascular repair may
prove to be much higher once this technique becomes as
widely available as conventional surgical treatment. There is
no immediate reason to assume, for instance, that low-
volume stent grafting will be any safer in the future than
low-volume open operations have been in the past.
One of the most gratifying aspects of open AAA repair
is its durability. We were able to identify only four late graft
complications (0.4%) among 1047 eligible patients in our
Table V. Additional Kaplan-Meier survival estimates
n
Survival estimates
P value1 year 5 years 10 years
Gender .072
Men 985 94% 75% 48%
Women 150 95% 75% 58%
Functional myocardial imaging*† .015
Normal 374 95% 81% 63%
Fixed scar 127 93% 80% 34%
Active ischemia 104 94% 72% 64%
Inconclusive‡ 31 97% 88% 56%
Not done 460 93% 71% 46%
Coronary angiography† .29
Normal or mild to moderate CAD 132 95% 72% 58%
Advanced but compensated CAD 239 93% 70% 44%
Severe correctable CAD 154 96% 79% 46%
Not done 567 94% 79% 50%
Replacement graft configuration .03
Straight 337 95% 75% 51%
Aortobiiliac 736 94% 76% 47%
Aortobifemoral 40 83% 63% 50%
Aortoiliac/femoral 22 100% 81% 81%
Wound complications .019
No 1097 95% 76% 49%
Yes 38 80% 52% 41%
*Dipyridamole-thallium scintigraphy (n  376) or dobutamine-stress echocardiography (n  276).
†Preoperative information unavailable for 39 patients.
‡Failed to attain at least 85% of predicted maximal heart rate during stress testing.
Table VI. Multivariable analysis of deaths
Significant risk factors Risk ratio 95% CI P value
Age  75 years 2.2 1.7, 2.8 .001
Prior CHF 2.1 1.3, 3.4 .004
COPD 1.5 1.2, 2.0 .001
Creatinine  2 mg/dL or prior dialysis 3.2 2.2, 4.6 .001
Replacement graft configuration .013
Straight 0.88 0.68, 1.1 .328
Aortobiiliac 1.0 (Reference set)
Aortobifemoral 1.9 1.1, 3.1 .021
Aortoiliac/femoral 0.34 0.11, 1.1 .066
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series. Plate et al33 reported a similar low incidence rate of
2.3% in 1087 referral patients at the Mayo Clinic in 1985,
and, at the same center, Hallett et al34 subsequently found
that the cumulative 5-year incidence rate of major graft
complications was only 7% in a population study (Olmsted
County, Rochester, Minn) of patients who underwent
open AAA procedures as long ago as 1957. The long-term
technical results of open AAA repair historically have been
so dependable, in fact, that they now are taken almost for
granted. Only scant long-term data are available for endo-
vascular repair, but Ohki et al35 have reported a reinterven-
tion rate of 10% in 239 patients, a few of whom had been
followed for as long as 9 years. Consequently, a consensus
exists that aortic stent grafts must be reassessed with CT
scanning at least every 6 months to detect graft migration,
to evaluate old endoleaks, to discover new endoleaks, and
to be certain that no interval expansion of the excluded
aneurysm sac has occurred.36 This surveillance also adds to
the base cost of endografting, which, largely because of the
price of stent grafts themselves, already exceeds that of
open repair, despite a shorter length of stay during the
index hospital admission.37,38
Our perspective concerning the appropriateness of
open AAA repair in patients at average or good risk is not
prejudiced by inexperience with aortic stent grafting at the
Cleveland Clinic. In the years 1999 and 2000, two new
members of our department (Daniel G. Clair, MD, and
Roy K. Greenberg, MD) primarily were responsible for a
total of nearly 400 endograft AAA procedures during a
period of time in which approximately 300 open infrarenal
AAA operations also were performed. Many of the patients
who underwent endograft repair during these 2 years did
not have compelling contraindications to standard surgical
management. Some of these patients were enrolled in on-
going device trials, but the choice of endovascular treat-
ment in others simply reflects the fact that there is no
unanimous opinion concerning the selection of patients for
endograft repair even among our own staff. Despite its
availability, however, the authors have confined their in-
tradepartmental referrals for stent grafting almost exclu-
sively to patients who have severe cardiopulmonary disease
or another relative indication, such as truncal obesity, a
hostile abdomen from multiple previous operations, or ex-
treme old age. We generally have found that patients at
average or good risk who specifically request endograft repair
frequently have learned about this “less invasive” approach
from the media or their personal physicians, were unaware
that it had complications of its own, and often will choose to
proceed with a traditional open procedure once they have
been informed regarding its established safety and durability.
The data in our report indicate once again that ad-
vanced age or a previous history of CHF, COPD, or renal
insufficiency is associated with a significantly higher inci-
dence rate of postoperative complications or late death after
open AAA repair. Other investigators have made the same
observations.39,40 All of these findings collectively suggest
to us that, until its long-term reliability has been estab-
lished, aortic stent grafting is best suited to patients who are
advanced in age or have truly serious medical comorbidi-
ties. The definition of what constitutes a comorbidity of
sufficient severity to satisfy cautious indications for endo-
vascular AAA repair undoubtedly will be refined as the late
results of the present generation of stent grafts become
clear and as future improvements in their technology make
these devices even more dependable. On the basis of their
initial success, it is entirely possible, perhaps even likely,
that aortic stent grafting ultimately will replace open repair
as the procedure of choice for infrarenal AAAs in all pa-
tients. However, this transition should be driven by long-
term data proving that the benefit of endovascular proce-
dures extends well beyond the relatively short period of
time that is necessary for most patients at average or good
risk to recover from a conventional operation. These data
simply are not yet available. Until they are, it is unreason-
able to abandon an open surgical approach that, with
experience, can be performed with attainable operative
mortality and late graft complication rates of 2% or less.
Table VII. Representative operative mortality rates
Year
Study
period Operations (n) Mortality rate (%)
Collective reviews
Hollier, Taylor, and Ochsner20 1992 1985-1991 3130 3.5
Ernst21 1993 1981-1992 6488 4.0
Zarins and Harris22 1997 1987-1992 2162 2.1
Multicenter experience
Canadian Aneurysm Study23 1989 1986 666 4.8
Veterans Administration24 1996 1991-1993 3419 4.9
United Kingdom Small Aneurysm Trial25 1998 1991-1993 563 5.8
Statewide audits
New York26 1992 1985-1987 3570 7.6
Michigan27 1994 1980-1990 8185 7.5
Maryland28 1999 1990-1995 2335 3.5
National Hospital Discharge Survey
Lawrence et al29 1999 1984-1994 32,389 8.4
Heller et al30 2000 1979-1997 358,521 5.6
Huber et al31 2001 1994-1996 16,450 4.2
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